FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4309426089> ?p ?o ?g. }

• W4309426089 endingPage "77" @default.
• W4309426089 startingPage "64" @default.
• W4309426089 abstract "Relevance . The need to create a domestic pneumococcal polyvalent vaccine is one of the main directions of the «Strategy for the development of vaccine prevention of infectious diseases for the period up to 2035». Aim . To evaluate the immunological efficacy and safety of the pneumococcal polysaccharide conjugate adsorbed thirteen-valent (PCV13) vaccine in the immunization of adults and children in theRussian Federation. Materials and methods . The immunological efficacy and safety of the pneumococcal polysaccharide conjugated adsorbed thirteen-valent vaccine were studied in a prospective comparative randomized double-blind study in parallel groups in adult volunteers aged 18 to 65 years and a multicenter open comparative study in parallel groups in young children. In a clinical study of adults, 60 volunteers were randomized into two groups according to the 1:1 scheme (groupI, n = 30; group II, n = 30). A clinical study in children included 119 volunteers aged 15 months who were divided according to the 1:1:1 scheme (group I, n = 39; group II, n = 40; group III, n = 40). The reference vaccine in both studies is Prevenar® 13 (Pfizer Inc., USA). Results . A clinical study in adults showed no statistically significant difference between the study groups according to the results of primary (the proportion of volunteers whose concentration of serotype-specific IgG to each of the 13 pneumococcal serotypes is equal to or exceeds the level of 0.35 mcg/ml (p > 0.039) before vaccination and 4 weeks after vaccination) and secondary criteria for evaluating effectiveness. Thus, the results obtained indicate a comparable level of immunogenicity of PCV13 with the comparison drug Prevenar®13 with a single intramuscular injection to healthy volunteers aged 18–65 years. Safety in both groups was comparable, 15 local reactions were registered, including 7 in group I volunteers who received the test drug, and 8 in comparison group volunteers. There were no statistically significant differences in the frequency of registered adverse events between the groups. Similar results were obtained with the immunization of children. For all 13 serotypes of the new PCV13 in relation to the reference drug, both primary and secondary criteria for assessing immunogenicity during immunization of children have been achieved (Difference ≤ 10% and GMC and GMT Ratio ≥ 0.5, respectively), which proves no less effectiveness of the pneumococcal polysaccharide conjugated adsorbed thirteen-valent vaccine compared with the reference vaccine Prevenar® 13. During the clinical study, a total of 27 adverse events were registered in children, which were associated with the introduction of vaccines and were represented by local and systemic reactions (5 AEs in study participants from group I (5/39) 12.80%, 18 AEs in study participants from group II (18/40) 45.0% and 4 AEs in study participants from group III (4/40) 10%). No SAEs were registered in this study. Conclusion . The obtained results of the researches in children and adults allow us to recommend the preparation pneumococcal polysaccharide conjugate adsorbed thirteen-valent vaccine for immunization in order to prevent pneumococcal infection, both adults and children according to the 2+1 scheme within the National vaccination schedule and the calendar of preventive vaccinations according to epidemic indications of the Russian Federation." @default.
• W4309426089 created "2022-11-27" @default.
• W4309426089 creator A5017626731 @default.
• W4309426089 creator A5030120482 @default.
• W4309426089 creator A5034993715 @default.
• W4309426089 creator A5044037634 @default.
• W4309426089 creator A5056400725 @default.
• W4309426089 creator A5062353262 @default.
• W4309426089 date "2022-11-19" @default.
• W4309426089 modified "2023-10-06" @default.
• W4309426089 title "Immunological Efficacy and Safety of a New Pneumococcal Polysaccharide Conjugated Thirteen-Valent Vaccine in the Immunization of Adults and Children (Results of Clinical Studies in the Russian Federation)" @default.
• W4309426089 cites W1968804963 @default.
• W4309426089 cites W2013109731 @default.
• W4309426089 cites W2040350179 @default.
• W4309426089 cites W2051453885 @default.
• W4309426089 cites W2074074587 @default.
• W4309426089 cites W2079255865 @default.
• W4309426089 cites W2147848943 @default.
• W4309426089 cites W2157583453 @default.
• W4309426089 cites W2169729911 @default.
• W4309426089 cites W2480507502 @default.
• W4309426089 cites W2587058138 @default.
• W4309426089 cites W2616519181 @default.
• W4309426089 cites W2888911213 @default.
• W4309426089 cites W2904457533 @default.
• W4309426089 cites W2941819222 @default.
• W4309426089 cites W2981074437 @default.
• W4309426089 cites W3000570230 @default.
• W4309426089 cites W3023936988 @default.
• W4309426089 cites W3117351681 @default.
• W4309426089 cites W3136326095 @default.
• W4309426089 cites W3153475690 @default.
• W4309426089 doi "https://doi.org/10.31631/2073-3046-2022-21-5-64-77" @default.
• W4309426089 hasPublicationYear "2022" @default.
• W4309426089 type Work @default.
• W4309426089 citedByCount "0" @default.
• W4309426089 crossrefType "journal-article" @default.
• W4309426089 hasAuthorship W4309426089A5017626731 @default.
• W4309426089 hasAuthorship W4309426089A5030120482 @default.
• W4309426089 hasAuthorship W4309426089A5034993715 @default.
• W4309426089 hasAuthorship W4309426089A5044037634 @default.
• W4309426089 hasAuthorship W4309426089A5056400725 @default.
• W4309426089 hasAuthorship W4309426089A5062353262 @default.
• W4309426089 hasBestOaLocation W43094260891 @default.
• W4309426089 hasConcept C10389963 @default.
• W4309426089 hasConcept C105639569 @default.
• W4309426089 hasConcept C126322002 @default.
• W4309426089 hasConcept C142724271 @default.
• W4309426089 hasConcept C144133560 @default.
• W4309426089 hasConcept C159654299 @default.
• W4309426089 hasConcept C168563851 @default.
• W4309426089 hasConcept C187212893 @default.
• W4309426089 hasConcept C203014093 @default.
• W4309426089 hasConcept C204787440 @default.
• W4309426089 hasConcept C22070199 @default.
• W4309426089 hasConcept C27081682 @default.
• W4309426089 hasConcept C2778866548 @default.
• W4309426089 hasConcept C2779301066 @default.
• W4309426089 hasConcept C2779664119 @default.
• W4309426089 hasConcept C2780801004 @default.
• W4309426089 hasConcept C2781253189 @default.
• W4309426089 hasConcept C2909654208 @default.
• W4309426089 hasConcept C2991744798 @default.
• W4309426089 hasConcept C3019953208 @default.
• W4309426089 hasConcept C3020803494 @default.
• W4309426089 hasConcept C501593827 @default.
• W4309426089 hasConcept C535046627 @default.
• W4309426089 hasConcept C71924100 @default.
• W4309426089 hasConcept C86803240 @default.
• W4309426089 hasConcept C89423630 @default.
• W4309426089 hasConceptScore W4309426089C10389963 @default.
• W4309426089 hasConceptScore W4309426089C105639569 @default.
• W4309426089 hasConceptScore W4309426089C126322002 @default.
• W4309426089 hasConceptScore W4309426089C142724271 @default.
• W4309426089 hasConceptScore W4309426089C144133560 @default.
• W4309426089 hasConceptScore W4309426089C159654299 @default.
• W4309426089 hasConceptScore W4309426089C168563851 @default.
• W4309426089 hasConceptScore W4309426089C187212893 @default.
• W4309426089 hasConceptScore W4309426089C203014093 @default.
• W4309426089 hasConceptScore W4309426089C204787440 @default.
• W4309426089 hasConceptScore W4309426089C22070199 @default.
• W4309426089 hasConceptScore W4309426089C27081682 @default.
• W4309426089 hasConceptScore W4309426089C2778866548 @default.
• W4309426089 hasConceptScore W4309426089C2779301066 @default.
• W4309426089 hasConceptScore W4309426089C2779664119 @default.
• W4309426089 hasConceptScore W4309426089C2780801004 @default.
• W4309426089 hasConceptScore W4309426089C2781253189 @default.
• W4309426089 hasConceptScore W4309426089C2909654208 @default.
• W4309426089 hasConceptScore W4309426089C2991744798 @default.
• W4309426089 hasConceptScore W4309426089C3019953208 @default.
• W4309426089 hasConceptScore W4309426089C3020803494 @default.
• W4309426089 hasConceptScore W4309426089C501593827 @default.
• W4309426089 hasConceptScore W4309426089C535046627 @default.
• W4309426089 hasConceptScore W4309426089C71924100 @default.
• W4309426089 hasConceptScore W4309426089C86803240 @default.
• W4309426089 hasConceptScore W4309426089C89423630 @default.
• W4309426089 hasIssue "5" @default.
• W4309426089 hasLocation W43094260891 @default.

• next